The Pharmacotherapy of Heparin-Induced Thrombocytopenia (HIT) : A Review of Contemporary Therapeutic Challenges in Clinical Practice.
Research article published in The Malaysian journal of medical sciences : MJMS (2008)
Abstract
Our objectives were to discuss a general overview on the description and recognition of heparin-induced thrombocytopenia (HIT) and present a critical review of the traditional and most recent advances in its pharmacotherapy. Computerized searches were done on MEDLINE and Iowa Drug Information Service (IDIS) databases from June 2001 until June 2007 and from May 2005 until May 2007, respectively. Search terms used included 'heparin-induced thrombocytopenia', 'heparin-associated thrombocytopenia', therapeutics, HIT, HAT. We largely selected publications within the timeframe above, but did not exclude commonly referenced and highly regarded older publications. The commonly referenced published articles were obtained through manual searches derived from bibliographic citations and retrievals from the authors' personal files. Pertinent literatures (89 key articles) that were thought to have substantially contributed new information to the therapeutics of HIT within the last 6 years were identified, reviewed and presented. The following limits were used for the MEDLINE and IDIS searches: 'human', drug therapy', 'review', 'meta-analysis', 'clinical trial', and case reports. The therapeutics of HIT is rapidly evolving and needs to consider an evidence - based approach. It is imperative that practitioners be aware of the associated risk and be up-to-date with the current advances in the management of this fatal clinical condition.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
The Pharmacotherapy of Heparin-Induced Thrombocytopenia (HIT) : A Review of Contemporary Therapeutic Challenges in Clinical Practice.
Warum dies für die Hirudotherapie relevant ist
Dieser Artikel präsentiert eine Literaturübersicht zur Erkennung und Pharmakotherapie der Heparin-induzierten Thrombozytopenie (HIT), die traditionelle und neuartige therapeutische Ansätze zusammenfasst, identifiziert durch systematische Datenbankrecherchen in MEDLINE und IDIS. Für ASHs Domäne ist HIT eine prothrombotische Komplikation der Heparintherapie – ein Zustand, dessen Management alternative Antikoagulanzien einschließt, von denen einige (z. B. direkte Thrombininhibitoren wie Bivalirudin oder Lepirudin) eine mechanistische Verwandtschaft mit Hirudin, dem archetypischen Thrombininhibitor aus dem Blutegelspeichel, aufweisen. Das Abstract erörtert jedoch nicht spezifisch Hirudin, aus Blutegeln gewonnene Wirkstoffe oder Hirudotherapie; die Relevanz ist allenfalls indirekt und auf die breitere Antikoagulationslandschaft beschränkt.
Zitation
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026